Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Once-daily pill suppressed HBV viral load in nearly two thirds of people with HIV/HBV coinfection.
People with HIV are at greater risk for hepatitis B but are less likely to get vaccinated and respond to vaccines.
Physical activity also reduces the risk of comorbidities that occur at higher rates in people living with HIV.
Universal HCV testing led to an increase in the number of pregnant women and infants diagnosed in a timely manner.
Only 30% of U.S. adults have been vaccinated against the liver disease. Here’s how the Hepatitis B Foundation aims to change that.
Noninvasive imaging may be the best way to screen for NAFLD in this population.
The PreHevbrio vaccine produces higher antibody levels and offers faster protection.
People with HIV had fewer cirrhosis-related complications but greater healthcare utilization.
Timely testing and treatment could improve outcomes for young people who inject drugs.
Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.
With no approved treatments, management of NAFLD and NASH relies on lifestyle changes.
Barriers still stand in the way of making treatment available to all who need it.
An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.
Suppression of hepatitis B virus with antiviral treatment lowered the risk of hepatocellular carcinoma by 58%.
The early cancer is detected, the easier it is to treat.
People living with both viruses remain at risk for hepatocellular carcinoma despite antiviral therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.